Zenas' stock drops 51% despite lead asset's Phase III rare disease win [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The B-cell inhibiting monoclonal antibody (mAb) triggered a statistically significant 56% reduction in the risk of Immunoglobulin G4-related disease (IgG4-RD) flare-ups in the INDIGO study (NCT05662241) – meeting its primary endpoint. However, the subcutaneous (SC) therapy failed to best its potential market competitor, Amgen's Uplizna (inebilizumab), which triggered an 87% risk reduction in its respective pivotal trial. Following the debut of these topline IgG4-RD results, investors have pulled away from Zenas' stock, causing its value to crash by more than 51.8% from $34.50 at market close on 2 January to $16.61 at market close on 5 January. Obexelimab also met all of its secondary trial endpoints – reducing the number of flares requiring rescue therapy and the general use of such treatments, while boosting the proportion of patients achieving complete remission. While Zenas is yet to share detailed information on obexelimab's safety profile, the biotech did note that patie
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]CNBC
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website